UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027358
Receipt number R000031351
Scientific Title Single arm and open-label study evaluating the effect of fucoidan intake on proviral load in carriers with human T-cell leukemia virus type-I
Date of disclosure of the study information 2017/05/17
Last modified on 2017/11/16 15:01:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Single arm and open-label study evaluating the effect of fucoidan intake on proviral load in carriers with human T-cell leukemia virus type-I

Acronym

Effect of fucoidan on proviral load in carriers with HTLV-1

Scientific Title

Single arm and open-label study evaluating the effect of fucoidan intake on proviral load in carriers with human T-cell leukemia virus type-I

Scientific Title:Acronym

Effect of fucoidan on proviral load in carriers with HTLV-1

Region

Japan


Condition

Condition

Human T-cell leukemia virus type-I (HTLV-1) infection

Classification by specialty

Hematology and clinical oncology Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of fucoidan on proviral load in HTLV-1 carriers

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

HTLV-1 proviral load (real-time PCR method)

Key secondary outcomes

fucoidan concentration in urine (ELISA), Immune function (flow cytometric analysis of cell surface marker)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Fucoidan-drink (fucoidan 1 g/50 ml/bottle, 3 bottles/day)for 6 months

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Those who are diagnosed as HTLV-1 carrier in Kariyushi-Hospital on Ishigaki Island, Okinawa, Japan
2. Aged 20 years or older
3. HTLV-1 proviral load >= 4 copies/100 peripheral mononuclear cells
4. Available to participate within the study time frame
5. Consent to participate for the study

Key exclusion criteria

1. Those who have developed HTLV-1 associated diseases (ATL, HAM/TSP, HU)
2. Those who suffered any other malignant tumor and receive medical treatment
3. Those who suffer from systemic infection
4. Those who receive medical treatment that might affect HTLV-1 proviral load

Target sample size

15


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takuya Fukushima

Organization

University of the Ryukyus

Division name

Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine

Zip code


Address

207 Uehara, Nishihara, Okinawa, Japan

TEL

+81-98-895-1276

Email

fukutaku@med.u-ryukyu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Megumi Kuba-Miyara

Organization

University of the Ryukyus

Division name

Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine

Zip code


Address

207 Uehara, Nishihara, Okinawa, Japan

TEL

+81-98-895-3331(ext.2652)

Homepage URL


Email

kubame93@med.u-ryukyu.ac.jp


Sponsor or person

Institute

University of the Ryukyus

Institute

Department

Personal name



Funding Source

Organization

Department of Agriculture, Forestry and Fisheries, Okinawa Prefectural Government

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

South Product Co., Ltd, Kariyushi Hospital, Jozen-kai Medical Corporation (Ishigaki Island, Okinawa)

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人上善会かりゆし病院(沖縄県)、琉球大学医学部保健学科血液免疫検査学分野


Other administrative information

Date of disclosure of the study information

2017 Year 05 Month 17 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 07 Month 01 Day

Date of IRB


Anticipated trial start date

2016 Year 08 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2017 Year 05 Month 31 Day


Other

Other related information



Management information

Registered date

2017 Year 05 Month 16 Day

Last modified on

2017 Year 11 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031351


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name